A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma

NCT02152774 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

New York Glaucoma Research Institute